This site is intended for US healthcare professionals.
This site is intended for
US healthcare professionals.

Evolving rrRCC Management

The Management of rrRCC
Is Rapidly Evolving

There is a lack of phase 3 data
beyond second line

Making clinical decisions is challenging in this rapidly changing field12

As a result of recent improvements in overall survival, there is a growing population of patients with highly refractory disease who have received prior checkpoint inhibitors and need new later-line treatment options13,14

Later-Line RCC Therapy Has Proven Benefits

Post−second-line treatment can offer meaningful efficacy

A retrospective analysis of treatment of 4824 International Metastatic Renal Cell Carcinoma Database Consortium patients found that mRCC patients who received third-line therapy had an increased median survival approximately twice that of those who did not receive treatment (14.9 vs 7.6 months, respectively).2

“The tolerability [of regimens] is an issue when considering third- and fourth-line therapies. By the fourth line, most patients are just beaten up by treatment, so you can only really discuss hospice care.”

– Community Oncologist

Third-Line Targeted Therapy
Demonstrated Improved Survival2*

*Versus no therapy.

Reprinted from European Urology, 71(2), Wells JC, Stukalin I, Norton C, et al. Third-line targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium, 204-220, 2017, with permission from Elsevier.

Kaplan-Meier curve showing OS from time of cessation of second-line therapy for patients receiving third-line therapy (n=715) or not (n=345), excluding patients who died within 3 months of cessation.

CI=confidence interval; OS=overall survival; rrRCC=relapsed/refractory renal cell carcinoma.